Patents for A61P 19 - Drugs for skeletal disorders (81,981)
07/1999
07/06/1999US5919775 Method for inhibiting expression of inducible nitric oxide synthase with tetracycline
07/06/1999US5919774 Novel compounds such as 2-(1-benzyl-2,5-dimethyl-4-(2-carboxyphenylmethyl)pyrrol-3-yl) glyoxamide for inhibiting human nonpancreatic secretory phospholipase a2 (spla2) mediated release of fatty acids in a mammal
07/06/1999US5919702 Collecting wharton's jelly from umbilical cords, culturing so that pre-chondrocytes proliferate, isolating pre-chondrocytes which give rise to chondrocytes which produce cartilage tissue for therapeutic use
07/06/1999US5919660 Human requiem
07/01/1999WO1999032620A1 Insulin-like growth factor binding protein fragments and the utilization thereof
07/01/1999WO1999032614A1 Secreted proteins and polynucleotides encoding them
07/01/1999WO1999032610A1 Human nucleotide pyrophosphohydrolase-2
07/01/1999WO1999032457A1 Novel acylguanidine derivatives as inhibitors of bone resorption and as vitronectin receptor antagonists
07/01/1999WO1999032452A1 Carboxyl acid substituted heterocycles as metalloproteinase inhibitors
07/01/1999WO1999032451A1 Azepine or larger medium ring derivatives and their use as pharmaceuticals
07/01/1999WO1999032448A1 Substituted pyridine and pyridazine compounds and their pharmaceutical use
07/01/1999WO1999032111A1 INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS
07/01/1999WO1999032110A1 INHIBITION OF p38 KINASE ACTIVITY USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS
07/01/1999WO1999031969A2 Transgenic animal model for degenerative diseases of cartilage
07/01/1999WO1999011292A3 Compositions and methods for treating arthritis utilizing gene therapy
07/01/1999DE19757250A1 Insulin-like growth factor binding protein und seine Verwendung Insulin-like growth factor binding protein and its use
07/01/1999CA2315974A1 Insulin-like growth factor binding protein fragments and the utilization thereof
07/01/1999CA2315788A1 Human nucleotide pyrophosphohydrolase-2
07/01/1999CA2315720A1 Inhibition of p38 kinase activity using substituted heterocyclic ureas
07/01/1999CA2315245A1 Secreted proteins and polynucleotides encoding them
07/01/1999CA2314357A1 Transgenic animal model for degenerative diseases of cartilage
07/01/1999CA2312712A1 Novel acylguanidine derivatives as inhibitors of bone resorption and as vitronectin receptor antagonists
06/1999
06/30/1999EP0926237A2 Nucleic acid constructs for gene therapy, whose activity is influenced by inhibitors of cyclin-dependent kinases
06/30/1999EP0926236A1 Binding partners for inhibitors of cyclin-dependent kinases and their use for inhibitor screening, diagnosis or therapy
06/30/1999EP0926137A1 Picolin acid derivatives useful in the treatment of IL-1 and TNF mediated diseases
06/30/1999EP0925359A1 Monoclonal antibodies against the extracellular domain of human vegf-receptor protein (kdr)
06/30/1999EP0925303A1 Phosphinic acid amides as matrix metalloprotease inhibitors
06/30/1999EP0925294A1 Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and method of reducing tnf-alpha levels
06/30/1999EP0925287A1 Heterocyclic metalloprotease inhibitors
06/30/1999EP0925071A1 Muc-1 as an immunosuppressive therapeutic agent for the treatment of inflammatory and autoimmune conditions
06/30/1999CN1221401A Calcilytic compounds
06/30/1999CN1220880A Medicinal powder for treatment of deferent duct stagnation and obstruction
06/29/1999US5916887 4-substituted-3-(2-amino-2-cycloalkyl methyl)-acetamido azetidin-2-one derivatives as cysteine proteinase regulators
06/29/1999US5916878 Dipeptide of either gamma-glutamyl-l-tryptophan or beta-aspartyl-l-tryptophan; administering to the patients to reduce the risks infections from microorganism
06/29/1999US5916870 Compositions and therapeutic methods using morphogenic proteins and stimulatory factors
06/29/1999US5916557 Methods of repairing connective tissues
06/29/1999US5916556 Human MRNA editing enzyme
06/24/1999WO1999031128A2 Human tumor necrosis factor-r2-like proteins
06/24/1999WO1999031126A1 Cyclopeptide derivatives with integrin inhibitor properties
06/24/1999WO1999031116A1 Human dendriac and brainiac-3
06/24/1999WO1999031112A1 Vitamin d derivatives with phosphorous atoms in the side chains
06/24/1999WO1999031099A1 Integrin receptor antagonists
06/24/1999WO1999031066A1 Pyridones as src family sh2 domain inhibitors
06/24/1999WO1999031061A1 Integrin receptor antagonists
06/24/1999WO1999031058A1 Novel heterocyclic compounds
06/24/1999WO1999030726A1 Improved method for attaching dental and orthopedic implants, ligaments, and tendons to bone
06/24/1999WO1999030713A1 Integrin receptor antagonists
06/24/1999WO1999030710A1 USE OF PYRAZOLO [3,4-b] PYRIDINE AS CYCLIN DEPENDENT KINASE INHIBITORS
06/24/1999WO1999030709A1 Integrin receptor antagonists
06/24/1999WO1999030670A2 Methods of treatment using novel ligands of the neuropeptide receptor hfgan72 and agonists or antagonists thereof
06/24/1999WO1999003516A3 Semi-interpenetrating polymer networks
06/24/1999CA2315370A1 Integrin receptor antagonists
06/24/1999CA2315232A1 Integrin receptor antagonists
06/24/1999CA2314884A1 Human tumor necrosis factor-r2-like proteins
06/24/1999CA2314379A1 Human dendriac and brainiac-3
06/24/1999CA2314355A1 Use of pyrazolo ¢3,4-b! pyridine as cyclin dependent kinase inhibitors
06/23/1999EP0924204A1 2-phenylmorpholin-5-one derivatives and pharmaceutical composition comprising the same
06/23/1999EP0923646A1 Vaccine compositions and methods useful in inducing immune protection against arthritogenic peptides involved in the pathogenesis of rheumatoid arthritis
06/23/1999EP0923582A1 Substituted 6,5-hetero-bicyclic derivatives
06/23/1999EP0923569A1 Butyric acid matrix metalloproteinase inhibitors
06/23/1999EP0923563A1 1,4-heterocyclic metallprotease inhibitors
06/23/1999EP0923561A1 Heterocyclic metalloprotease inhibitors
06/23/1999EP0923552A1 Pyranoindole and carbazole inhibitors of cox-2
06/23/1999EP0923547A1 Bidentate metalloprotease inhibitors
06/23/1999EP0923535A1 Inhibitors of cysteine protease
06/23/1999EP0923529A1 Subsitute 4-arylbutyric acid derivatives as matrix metalloprotease inhibitors
06/23/1999EP0923377A1 Therapeutic uses for an aminosterol compound
06/23/1999CN1220609A Growth hormone component and bone anti-resorptive agent in cyclic (coherence) treatment of osteoporosis
06/23/1999CN1220146A Health-care medicinal liquor for curing rheumatic disease
06/23/1999CA2222770A1 Method of treating rheumatoid arthritis with low dose type ii collagen
06/22/1999US5914323 Treating hypercalcemia of malignancy, metastatic bone disease and/or metabolic bone disease by administering an isotonic aqueous alendronate solution with a buffer to maintain the ph in the range 4 to 8 to prevent precipitation
06/22/1999US5914111 Inhibiting t-cell activation by administering polypeptide having amino acids 1-92 of lymphocyte functioning associated antigen-3 joined to different protein or polypeptide comprising portion of immunoglobulin
06/22/1999US5914106 Interleukin-6 receptor agonists
06/20/1999CA2255143A1 Binding partners for inhibitors of cyclin-dependent kinases and their use for searching for inhibitors and for the diagnosis or therapy of a disease
06/20/1999CA2255141A1 Nucleic acid constructs for gene therapy whose activity is affected by inhibitors of cyclin-dependent kinases
06/17/1999WO1999030157A2 Neuropilins in methods for diagnosis and prognosis of cancer
06/17/1999WO1999029878A2 Methods of producing anti-angiogenic proteins: endostatin, angiostatin or restin, using a pichia yeast expression system
06/17/1999WO1999029861A1 Peptide antagonists of vascular endothelial growth factor
06/17/1999WO1999029858A1 Soluble inhibitors of vascular endothelial growth factor and use thereof
06/17/1999WO1999029856A1 Restin and methods of use thereof
06/17/1999WO1999029855A1 Mutants of endostatin, 'em 1' having anti-angiogenic activity and methods of use thereof
06/17/1999WO1999029726A1 Phospholipase inhibitor
06/17/1999WO1999029667A1 Hydroxamic acid derivatives as matrix metalloprotease (mmp) inhibitors
06/17/1999WO1999029661A1 Adamantane derivatives
06/17/1999WO1999029660A1 Adamantane derivatives
06/17/1999WO1999029316A1 Pharmaceutical compositions containing an omega-3 fatty acid oil
06/17/1999WO1999009162A3 Delayed progression to aids by a missense allele of the ccr2 gene
06/17/1999DE19755800A1 Cyclopeptidderivate Cyclopeptide derivatives
06/17/1999CA2313705A1 Restin and methods of use thereof
06/17/1999CA2313390A1 Peptide antagonists of vascular endothelial growth factor
06/17/1999CA2313348A1 Soluble inhibitors of vascular endothelial growth factor and use thereof
06/17/1999CA2313251A1 Mutants of endostatin, "em 1" having anti-angiogenic activity and methods of use thereof
06/17/1999CA2312889A1 Adamantane derivatives
06/17/1999CA2312420A1 Adamantane derivatives
06/17/1999CA2312287A1 Methods of producing anti-angiogenic proteins: endostatin, angiostatin or restin, using a pichia yeast expression system
06/16/1999EP0922111A1 Induction of t cell tolerance using a soluble molecule that can simultaneously block two costimulatory pathways
06/16/1999EP0922030A1 Arylsulfonylamino hydroxamic acid derivatives
06/16/1999EP0583421B1 Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
06/16/1999CN1219965A Promotion of regeneration of organized tissues
06/16/1999CN1219936A New triazolopurines, method of preparing them and their use as drugs